No abstract available.
Alendronate* ; Animals ; Diphosphonates ; Rats*

No abstract available.
Alendronate* ; Animals ; Rats*

No abstract available.
Alendronate ; Cell Proliferation

No abstract available.
Alendronate ; Humans ; Osteoporosis ; Vitamin D ; Vitamins

No abstract available.
Alendronate ; Humans ; Osteoporosis ; Vitamin D ; Vitamins

PURPOSE: Alendronate has been proposed as a local and systemic drug treatment used as an adjunct to scaling and root planing (SRP) for the treatment of periodontitis. However, its effectiveness has yet to be conclusively established. The purpose of the present meta-analysis was to assess the effectiveness of SRP with alendronate on periodontitis compared to SRP alone. METHODS: Five electronic databases were used by 2 independent reviewers to identify relevant articles from the earliest records up to September 2016. Randomized controlled trials (RCTs) comparing SRP with alendronate to SRP with placebo in the treatment of periodontitis were included. The outcome measures were changes in bone defect fill, probing depth (PD), and clinical attachment level (CAL) from baseline to 6 months. A fixed-effect or random-effect model was used to pool the extracted data, as appropriate. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using the Cochrane χ² and I2 tests. RESULTS: After the selection process, 8 articles were included in the meta-analysis. Compared with SRP alone, the adjunctive mean benefits of locally delivered alendronate were 38.25% for bone defect fill increase (95% CI=33.05–43.45; P<0.001; I²=94.0%), 2.29 mm for PD reduction (95% CI=2.07–2.52 mm; P<0.001; I²=0.0%) and 1.92 mm for CAL gain (95% CI=1.55–2.30 mm; P<0.001; I²=66.0%). In addition, systemically administered alendronate with SRP significantly reduced PD by 0.36 mm (95% CI=0.18–0.55 mm; P<0.001; I²=0.0%) and increased CAL by 0.39 mm (95% CI=0.11–0.68 mm; P=0.006; I²=6.0%). CONCLUSIONS: The collective evidence regarding the adjunctive use of alendronate locally and systemically with SRP indicates that the combined treatment can improve the efficacy of non-surgical periodontal therapy on increasing CAL and bone defect fill and reducing PD. However, precautions must be exercised in interpreting these results, and multicenter studies evaluating this specific application should be carried out.
Alendronate* ; Outcome Assessment (Health Care) ; Periodontitis* ; Population Characteristics ; Root Planing*

OBJECTIVES: To evaluate the effect of postmenopausal hormone therapy alone or in combination with bisphosphonate on bone mineral density (BMD) in postmenopausal women. METHODS: One hundred three women diagnosed with low BMD in postmenopausal women were included in this study. All patients were classified into two groups; oarl hormone therpy alone (Group I) or with alendronate (Group II), given for 12 months. Dual energy X-ray absorptiometry was used to measure BMD before and after 12 months of treatment. RESULTS: In all groups, significant increase in bone density measurements were seen at 12 months of treatment. The BMD of lumbar spine more increased significantly in Group II than Group I. CONCLUSIONS: Postmenopausal hormone therapy is effective in osteopenic and osteoporotic women. However, the combined treatment with hormone therapy and bisphophonate is more effective in postmenopausal women with low BMD.
Absorptiometry, Photon ; Alendronate ; Bone Density ; Female ; Humans ; Menopause ; Spine

PURPOSE: To evaluate the changes in bone mineral density (BMD) after alendronate intake and to determine the side effects and patient compliance. MATERIALS AND METHODS: Two hundred twelve patients with osteoporosis were treated with alendronate. One hundred sixty-two patients were excluded because of early discontinuation. Thus, 50 patients were included in the analysis. RESULTS: The annual increase in BMD in patients taking alendronate was 7.2% (1st year), 3.4%, 2.0%, and 0.9% (4th year) in the L-spine, and 2.2%, 1.5%, -0.9%, and 0.9% in the femur. The changes in BMD of patients< 60 years of age were 2.1% in the L-spine and 3.4% in the femur. The BMD of patients between 60 and 69 years of age increased 6.3% and 0.5% in the L-spine and femur, respectively, and the BMD of patients >70 of age were 2.9% and 1.2% in the L-spine and femur, respectively. The BMD changes in patients with a T-score< -4.0 were 7.0% (L-spine) and 1.2% (femur), the BMD changes in patients with a T-score between -3.0 and -3.9 were 5.3% and 0.2% for the Lspine and femur, respectively, and the BMD changes in patients with a T-score >3.0 were 2.5% and 3.1% for the Lspine and femur, respectively. The reasons for early discontinuation of alendronate were difficulty in intake, economic reasons, and adverse events. CONCLUSION: The BMD changes were greater in the L-spine than the femu in alendronate users. At the first year, the changes in BMD was greatest. There was no significant difference in BMD change according to age. In the Lspine, however, BMD changes were greater in the group with lower T-scores. The early discontinuance rate was 74%, and the adverse events rate was 19.8%.
Alendronate ; Bone Density ; Femur ; Humans ; Osteoporosis ; Patient Compliance

PURPOSE: The aim of this study was to observe the bony change in the OVX rat longitudinally and to study the alendronate effect. MATERIALS AND METHODS: Eighteen Sprague-Dewley rats, eight-week old each, were randomly assigned into three groups: one of those sham-operated (N=4), the other two were OVX: saline-treated (N=7) and alendronate-treated group (N=7). The saline-treated group was administered with saline solution (0.1 mL/100 g) daily, while the alendronate- treated group was given alendronate (1 mg/kg, Sigma-Aldrich Corp. Korea) daily. Micro-CT scannings of the lumbar were consecutively done at baseline, at 3-week intervals during 9 weeks. Two and three dimensional bony analysis were done. Bone mineral density (BMD) was measured with Piximus (GE Lunar Co. USA). The average values of these three methods were compared with each group. RESULTS: After 6 weeks the BMD of the OVX group showed lower tendency than that of sham group. After 6 weeks many 3D parameters of micro-CT showed higher values in the OVX-alendronate group compared with the OVXsaline group. Most 2D bony parameters were higher in the OVX-alendronate group compared with the OVX-saline group at 9 weeks. CONCLUSION: This study showed low BMD of the OVX group after 6 weeks and showed the effect of alendronate on the BMD and bony structures of ovariectomized rats. This study also showed usefulness of in vivo micro-CT in monitoring individual bone changes over time.
Alendronate ; Animals ; Bone Density ; Female ; Ovariectomy ; Rats ; Salicylamides ; Sodium Chloride ; Tomography, X-Ray Computed

OBJECTIVE: To assess the efficacies of once-weekly bisphosphonates on bone mineral density (BMD) gains in Korean women aged 50 years or more. METHODS: We selected 166 patients who received: alendronate 70 mg (n=48), alendronate 70 mg + cholecalciferol 2,800 IU (n=31) or risedronate 35 mg (n=87) for one year. The baseline BMD and the % changes of BMD at one-year were compared among the three medication groups. RESULTS: The menopausal status and number of women with osteoporosis was not different among the three groups, but mean age of women was significantly lower in alendronate group. Baseline BMD at L1-4 and femur neck (FN) was similar, but baseline BMD at femur total (FT) was significantly lower in alendronate group. After one-year use, the median % changes of BMD at three sites were similar among the three groups; however, the median values were highest in alendronate + cholecalciferol group (L1-4: 4.48%, 6.74%, and 4.50%; FT: 2.09%, 3.70%, and 2.31%; FN: 3.05%, 3.79%, and 2.03%). CONCLUSION: Among three once-weekly bisphosphonates, BMD gains were highest after one-year use of alendronate+cholecalciferol, although statistically not significant.
Aged ; Alendronate ; Bone Density ; Cholecalciferol ; Diphosphonates ; Etidronic Acid ; Female ; Femur ; Femur Neck ; Humans ; Osteoporosis ; Risedronate Sodium